What is intra-arterial (IA) angio-embolisation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Intra-Arterial (IA) Angioembolisation?

Intra-arterial angioembolisation (also called angiographic embolization or AG/AE) is a minimally invasive endovascular procedure where embolic materials (such as particles, coils, or microspheres) are delivered through a catheter directly into arteries feeding a target lesion to occlude blood flow and achieve hemostasis or tumor control.

Mechanism and Technique

The procedure involves:

  • Arterial access via femoral or radial artery approach
  • Selective catheterization of the target vessel using fluoroscopic guidance
  • Delivery of embolic agents (PVA particles, coils, gelfoam, or drug-eluting beads) to occlude the bleeding vessel or tumor-feeding artery
  • Immediate hemostasis through mechanical occlusion and thrombosis of the target vessel

The embolic materials are chosen based on the clinical indication—particles (300-500μm) for distal occlusion, coils (2-3mm) for proximal control, or specialized agents like drug-eluting beads for oncologic applications 1.

Primary Clinical Applications

Trauma Management (Hemorrhage Control)

In hemodynamically stable trauma patients with arterial blush on CT scan, AG/AE should be considered as a first-line intervention 2. The 2020 WSES guidelines provide clear algorithmic guidance:

  • First-line use: Hemodynamically stable patients with contrast extravasation (arterial blush) on CT imaging should undergo AG/AE rather than immediate surgery (GoR 2B)
  • Therapeutic indication: Documented active bleeding in liver, spleen, kidney, or adrenal injuries significantly reduces non-operative management failure rates 3
  • Post-operative rescue: Persistent arterial bleeding after damage control surgery or non-hemostatic procedures warrants AG/AE (GoR 2A) 2
  • Delayed hemorrhage: Bleeding without severe hemodynamic compromise should be managed first with AG/AE (GoR 2A) 2
  • Pseudoaneurysm management: Hepatic artery pseudoaneurysms must be treated with AG/AE to prevent rupture (GoR 2A) 2

Critical caveat: In hemodynamically unstable non-responders, immediate operative management takes precedence over angioembolisation 2. However, in patients showing transient response to fluid resuscitation, AG/AE can be safe and effective even with hypotension 3.

Oncologic Applications

Transarterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (BCLC stage B) 4. The procedure combines:

  • Intra-arterial delivery of chemotherapy (doxorubicin, epirubicin, cisplatin) emulsified with Lipiodol
  • Followed by particle embolization to achieve vascular stagnation
  • Results in both cytotoxic effect and tumor ischemia

TACE should NOT be used in patients with decompensated liver disease, advanced liver/kidney dysfunction, macroscopic vascular invasion, or extrahepatic spread (evidence high; recommendation strong) 4.

Alternative embolization techniques include:

  • Transarterial bland embolization (TAE): Plain microspheres without chemotherapy
  • Transarterial radioembolization (TARE): Yttrium-90 microspheres for targeted radiation delivery 5

Safety Profile and Outcomes

The procedure is minimally invasive with favorable safety outcomes:

  • Recovery is practically painless compared to surgical alternatives 1
  • Lower complication rates than open surgery
  • Reduced hospitalization duration—often performed as outpatient procedure 5
  • In trauma, 100% technical success rate reported even in hypotensive patients with transient fluid response 3

Common pitfalls to avoid:

  • Do not perform preventive embolization indiscriminately—it's very effective in liver injuries with contrast blush but controversial in splenic trauma and provides no benefit in high-grade kidney injuries 3
  • In hemodynamically stable children with liver trauma, contrast blush is NOT an absolute indication for AG/AE (GoR 2B) 2
  • Requires immediate availability of trained interventional radiologists and appropriate imaging equipment 2

Clinical Decision Algorithm

For trauma patients:

  1. Hemodynamically unstable non-responders → Immediate operative management
  2. Hemodynamically stable with arterial blush on CT → AG/AE as first-line (GoR 2B)
  3. Transient responders to resuscitation → AG/AE can be attempted if immediately available
  4. Post-operative persistent bleeding → AG/AE as rescue therapy (GoR 2A)
  5. Delayed hemorrhage without severe compromise → AG/AE first-line (GoR 2A)

For oncologic indications:

  • HCC BCLC stage B → TACE as standard of care
  • Small renal masses → Thermal ablation preferred over embolization 5
  • Contraindications present (decompensation, vascular invasion) → Avoid TACE

The procedure represents a paradigm shift from traditional surgical approaches, offering targeted therapy while preserving surrounding healthy tissue 5.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.